PEGBIO CO-B

2565
3.2200.92% ( -0.030 )
Delay Closed: Nov 16, 16:08:11

Overview

PEGBIO CO-B (2565)

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119,...

Open
3.625
High
3.795
Low
3.220
Prev. Close
3.250
Volume
59.26M
Turnover
207.62M
Avg Price
3.503
Bid/Ask Ratio
41.08%
Amplitude
17.69%
52wk High
77.000
Volume Ratio
2.21
Turnover Ratio
14.36%
52wk Low
3.050
HK Mkt Cap
1.33B
Market CapHKD
1.35B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.912
EPSDynamic
-1.19
EPSStatic
--
BVPS
0.74
P/B
4.38
HK Shares
412.82M
Dividend YieldTTM
--
DividendTTM
--
Shares
417.90M
Min lot size
50
Currency
HKD

Daily Events

  1. Nov, 16

    PegBio (2565.HK) gapped up 11.5% to HK$3.625 but then weakened through the whole session, closing at HK$3.220, down 0.92% and at the day's low, on 59.07 million shares and a 14.31% turnover rate, as the benefit from Paidakang's inclusion in China's 2026 NRDL was cashed in after a roughly 12% jump the prior day. The business remains pre-revenue and loss-making: the Q2 2026 loss per share of HK$0.3192 widened 130.48% year on year, and the net loss of HK$124.8 million widened 143.37%. The stock is down 95.35% year to date, 95.82% below its 52-week high of HK$77, only 5.57% above its 52-week low of HK$3.05, and trades below both MA20 (HK$3.494) and MA60 (HK$4.741). A supply overhang remains from the early-November placement of 26.813 million new H shares at a 19% discount, which raised about HK$80.04 million net.

  2. Nov, 12

    PegBio opened at HK$3.220 and reversed higher to close at HK$3.375, up 3.5% from HK$3.260 on HK$67.9 million turnover, after completing a 19%-discounted placing of 26,813,000 new H shares. The session was not one-way: the stock spiked to HK$3.435 at 13:31, slid back to HK$3.260 by 14:38 and recovered into the close. The HK$80.04 million raise, with net proceeds above HK$77 million, adds cash, yet Q2 net loss widened 143% year-on-year to HK$124.8 million, EPS was -HK$0.3192 and ROE -162%, with no revenue recorded. Year to date the stock is down 95.13%, 95.62% below its 52-week high of HK$77 and only 10.66% above the HK$3.05 low, still under MA20 of HK$3.569 and MA60 of HK$4.831. Though the dilution from the discounted placement still needs to be absorbed.

  3. Nov, 11

    PegBio (2565.HK) fell 7.0% to HK$3.255 from a HK$3.500 previous close, as the completion of a placing at a 19% discount—26.813 million new H shares raising HK$80.04 million—drove dilution concerns and dominated the afternoon selloff. The intraday pattern was a spike-and-fade: after a HK$3.445 open, the stock printed a morning high of HK$3.485, then slid to HK$3.250 at 15:53 BJ and closed near the session low on 17.24 million shares worth HK$58.16 million. The price position remains weak: it is down 95.3% year-to-date, 95.77% below its 52-week high of HK$77, only 6.7% above the HK$3.05 low set on November 3, and sits under both its 20-day moving average of HK$3.62 and 60-day moving average of HK$4.874. The Q2 net loss was HK$124.8 million, 143.37% wider year-on-year, operating loss was HK$117.2 million, EPS was -HK$0.3192, down 130.48% year-on-year, and ROE was -162.03%; revenue was not disclosed, market capitalization is HK$1.36 billion, PB is 4.43x and PE is negative at -3.57x. Though the placement proceeds are now in hand, the pace at which the new shares are absorbed remains the key near-term overhang.

  4. Nov, 10

    PegBio (2565.HK) closed down 5.4% at HK$3.50, a spike-and-fade session: it opened at HK$3.48, dipped to HK$3.435 at 09:36, rallied to an intraday HK$3.680 at 14:42, then gave back the entire gain to settle at HK$3.500 in the closing auction on 31.8 million shares worth HK$112.9 million. The overhang remains the 19%-discount placement of 26.813 million shares for net proceeds of about HK$77.16 million earmarked for metabolic pipeline R&D, which cut the stock nearly 14% on announcement day and left it down 7.33% last week, with today's roughly 6% drop extending that move. Offsetting headlines centred on expectations that PB-119 enters China's national reimbursement drug list, which earlier lifted the shares more than 10% intraday. The price position is stark: down 94.95% year-to-date from HK$69.25, 95.45% below the 52-week high of HK$77.00 set on 27 November 2025, only 14.75% above the 52-week low of HK$3.05, and below both the MA20 of HK$3.688 and MA60 of HK$4.923, with a HK$1.37 billion market cap, PB of 4.46 and negative PE. A turnover rate of 8.25% suggests discounted stock is still being absorbed.

  5. Nov, 9

    PegBio (2565.HK) opened lower but gathered strength in the afternoon, jumping from HK$3.425 to a HK$3.730 intraday high in the closing hour and settling at HK$3.700, up 8.35% on HK$64.3 million turnover. The move extends a rebound built on expectations that lead candidate PB-119 (vipegrutide) will enter China's national reimbursement drug list, a theme that earlier lifted the shares more than 30% in one session. That optimism runs against a fresh HK$77.16 million net placement of 26.813 million shares at a 19% discount, which knocked the stock nearly 14% on announcement day and leaves a dilution overhang. Earnings remain loss-making: Q2 2026 net loss of HK$124.8 million, 143.37% wider year on year, with price-to-book at 4.71x. The shares are down 94.66% year to date and 95.19% below the 52-week high of HK$77, sitting just under the MA20 of HK$3.74 and far below the MA60 of HK$4.968, while still 21.31% above the 52-week low of HK$3.05. Whether placement proceeds translate into pipeline progress is unproven.

News